• PLD Surgical Treatment is aimed at de-bulking a massively large cystic liver.
• PLD Medical Treatment interferes with liver cyst cell wall receptors that trigger growth.
a gathering of our collective information, several helpful specialists with a great understanding of Polycystic Liver Disease have emerged: Dr. Torres is at the Mayo Clinic in Rochester, Minnesota USA. He is a beacon of light amidst a fog of knowledge about PLD. Listen to a lecture by Dr. Torres on PLD. He is a helpful and caring physician and a contributor to most of the current PLD Polycystic Liver Disease research. An excellent liver resection surgeon
is Dr. D. M. Nagorney also from the Mayo Clinic. Dr. Ubara in Japan achieves about a 40% reduction in
overall cystic liver size with hepatic artery ablation. If liver pain becomes chronic
requiring opiods for relief, there is a procedure called splanchnic
denervation useful for relieving pain that opiods fail
to touch. A few well
chosen unique individuals have undergone extensive laparoscopic
liver cyst deroofing for pain. This procedure provides temporary pain relief and oftentimes needs repeating.
• proton pump inhibitors
• eliminating dairy
• eliminating caffeine
• eliminating hormones
• eliminating estrogen disruptors
• diet has brought some success
• eliminating dairy
• possibly octreotide lanreotide, sandostatin LAR still experimental are not yet released for the treatment of PLD
• liver dialysis has the possibility of offering some temporary relief should a cystic liver should ever fail.
|We are hopeful
that Octreotide clinical
trials to shrink liver cysts will open another non-surgical treatment for PLD. Octreotide clinical trials are currently taking place in Italy, Belgium, the Netherlands and at the Mayo Clinic in Rochester, Minnesota USA. Dr. Drenth in Holland is another PLD researcher, also running clinical trials with octreotide in Holland and Belgium. Negri Mario Institute in Italy has a current three year follow up octreotide clinical trial.
Prior to octreotide trials some exciting results were published by the Mayo Clinic in the GastroEnterology Journal. Animal studies with Octreotide dramatically decreased liver and kidney cyst growth. Octreotide is a somatostatin analogue. It stimulates somatostatin receptors and this decreases cyclic AMP within the cyst. Decreasing cyclic AMP diminishes cyst growth. According to the article in Gastro Enterology, within liver cholangiocytes and within the serum of Polycystic rats, these contained approximately 2 times higher concentrations of cAMP than in the normal rats. Researchers are hopeful that clinical trials with Octreotide will prove useful in diminishing liver cysts in humans and also may be helpful for Caroli's Disease and ARPKD as well.